Tags

Type your tag names separated by a space and hit enter

Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis.
Ann Pharmacother 2007; 41(1):86-94AP

Abstract

OBJECTIVE

To assess the efficacy, toxicity, and potential cost benefit of palifermin in the prevention of chemotherapy- and radiation-induced mucositis.

DATA SOURCES

MEDLINE and PubMed database searches were conducted (1966-May 2006) using the following search terms: palifermin, human keratinocyte growth factor, fibroblast growth factor, mucositis, and stomatitis.

STUDY SELECTION AND DATA EXTRACTION

All published clinical trials and abstracts examining the use of palifermin, as well as information from the manufacturer, were included.

DATA SYNTHESIS

Severe mucositis resulting from anticancer therapies increases healthcare expenditures and negatively impacts patients' quality-of-life. Radiation therapy to the head and neck, as well as stem cell transplant conditioning regimens, have the highest incidence of severe mucositis. Consequences include prolonged hospitalization, need for parenteral nutrition, increased risk of infection, and severe pain. Palifermin is a recombinant human keratinacyte growth factor indicated in patients with hematologic malignancies who are undergoing stem cell transplant. In a randomized, placebo-controlled, Phase III trial, palifermin significantly reduced the incidence and duration of severe mucositis and days of parenteral nutrition and opioid analgesics in patients undergoing autologous stem cell transplant. The most common adverse effects of palifermin were rash, pruritus, cough, and taste alterations. Data in patients with solid tumors are limited, and there is a theoretical risk of stimulating tumor growth.

CONCLUSIONS

Treatment with palifermin appears to decrease the severity and duration of severe mucositis following autologous stem cell transplant. Use in these patients appears justified; however, use in non-stem cell transplant patients should be discouraged until more efficacy and toxicity data are available.

Authors+Show Affiliations

Brigham and Women's Hospital, Boston, MA, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17190850

Citation

McDonnell, Anne M., and Kristi L. Lenz. "Palifermin: Role in the Prevention of Chemotherapy- and Radiation-induced Mucositis." The Annals of Pharmacotherapy, vol. 41, no. 1, 2007, pp. 86-94.
McDonnell AM, Lenz KL. Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis. Ann Pharmacother. 2007;41(1):86-94.
McDonnell, A. M., & Lenz, K. L. (2007). Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis. The Annals of Pharmacotherapy, 41(1), pp. 86-94.
McDonnell AM, Lenz KL. Palifermin: Role in the Prevention of Chemotherapy- and Radiation-induced Mucositis. Ann Pharmacother. 2007;41(1):86-94. PubMed PMID: 17190850.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis. AU - McDonnell,Anne M, AU - Lenz,Kristi L, Y1 - 2006/12/26/ PY - 2006/12/28/pubmed PY - 2007/3/24/medline PY - 2006/12/28/entrez SP - 86 EP - 94 JF - The Annals of pharmacotherapy JO - Ann Pharmacother VL - 41 IS - 1 N2 - OBJECTIVE: To assess the efficacy, toxicity, and potential cost benefit of palifermin in the prevention of chemotherapy- and radiation-induced mucositis. DATA SOURCES: MEDLINE and PubMed database searches were conducted (1966-May 2006) using the following search terms: palifermin, human keratinocyte growth factor, fibroblast growth factor, mucositis, and stomatitis. STUDY SELECTION AND DATA EXTRACTION: All published clinical trials and abstracts examining the use of palifermin, as well as information from the manufacturer, were included. DATA SYNTHESIS: Severe mucositis resulting from anticancer therapies increases healthcare expenditures and negatively impacts patients' quality-of-life. Radiation therapy to the head and neck, as well as stem cell transplant conditioning regimens, have the highest incidence of severe mucositis. Consequences include prolonged hospitalization, need for parenteral nutrition, increased risk of infection, and severe pain. Palifermin is a recombinant human keratinacyte growth factor indicated in patients with hematologic malignancies who are undergoing stem cell transplant. In a randomized, placebo-controlled, Phase III trial, palifermin significantly reduced the incidence and duration of severe mucositis and days of parenteral nutrition and opioid analgesics in patients undergoing autologous stem cell transplant. The most common adverse effects of palifermin were rash, pruritus, cough, and taste alterations. Data in patients with solid tumors are limited, and there is a theoretical risk of stimulating tumor growth. CONCLUSIONS: Treatment with palifermin appears to decrease the severity and duration of severe mucositis following autologous stem cell transplant. Use in these patients appears justified; however, use in non-stem cell transplant patients should be discouraged until more efficacy and toxicity data are available. SN - 1542-6270 UR - https://www.unboundmedicine.com/medline/citation/17190850/Palifermin:_role_in_the_prevention_of_chemotherapy__and_radiation_induced_mucositis_ L2 - http://journals.sagepub.com/doi/full/10.1345/aph.1G473?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -